Prohep: Innovative Microbial Therapy for Liver Health and Cancer Prevention

Prohep is a groundbreaking microbial therapy designed for the prevention and treatment of liver diseases, including liver cancer, MASLD, and hyperlipidemia. Unlike conventional chemotherapy, targeted therapy, or immunotherapy—which face challenges such as high recurrence, short survival time, severe side effects, and high costs—Prohep offers a safer and more economical solution.

Key Advantages:

• Prevents liver cancer recurrence and effectively improves survival rates.

• Reduces hyperlipidemia symptoms while improving patient quality of life.

• Patented technology, ensuring exclusivity and strong market potential.

• Supported by university-led scientific research and clinical expertise.

Market Potential:

• Liver cancer remains a leading cause of death in China, with 367,700 new cases annually and a global treatment cost exceeding $40 billion.

• Prohep’s dual positioning—first as a supplement food (ProheB+) and later as an OTC drug—maximizes both near-term revenue and long-term clinical adoption.

Roadmap:

• Commercial rollout of ProheB+ in Asia.

• Clinical studies and patent expansion.

• Angel round fundraising of HKD 20M to support research, trials, and global market entry.

Vision:

Prohep is positioned to transform liver disease prevention and treatment, bridging the gap between scientific innovation and accessible healthcare. With a scalable business model and strong team of global experts, it represents a unique investment opportunity in the next generation of microbial therapies.